Global Market Analysis on Bone Growth Stimulator Offering Trends, Share, Size, Growth Until the End of 2022 | Competition Landscape- Ossatec Benelux B.V., Elizur Corporation, Johnson & Johnson, Arthrex, DJO Global, Stryker Corporation, Bioventus, Zimmer B

Bone growth stimulators are supplemental medical devices worn by patients following a cervical or lumbar spine surgery. Bone growth stimulators are utilized in boosting the natural fusion of spinal bone after fracture. Advanced bone growth stimulators can also facilitate multi-level fusions, the efficiency of which plays a pivotal role in spine fusion aftercare of patients. 

A latest report by Fact.MR projects the global bone growth stimulators market to account for revenues worth US$ 1,477.2 Mn in 2017. The market is estimated to exhibit a steady expansion during the forecast period. Various devices are developed for bone growth stimulation therapy, which are being highly demanded on the back of growing cases of accidental bone injuries across the globe.

Request For Free Sample Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=54

Key Forecast Highlights

According to the report, bone growth stimulation devices will account for nearly 56% share on global bone growth stimulator revenues in 2017. Platelet-rich plasmas, on the other hand, will be observed as promising product segment, revenues from which are expected to showcase robust growth at 6.2% CAGR. By the end of 2022, a little over US$ 450 Mn worth of platelet-rich plasmas will be sold in the global market for bone growth stimulators.
In the view of poor road infrastructure and inferior healthcare facilities existing in the Asia-Pacific excluding Japan (APEJ) region, the demand for bone growth stimulators is expected to gain grounds. These factors are boosting the incidence of spinal fractures in this region, compelling doctors towards adoption of bone growth simulation therapy. Moreover, manufacturers of bone growth stimulators are expected to benefit from low wage costs and high resource availability by setting up their manufacturing units across APEJ region. By the end of 2022, over US$ 225 Mn worth of bone growth stimulators will be sold across the APEJ market.
North America is expected to remain the largest market for bone growth stimulator. The report predicts that high healthcare spending implemented in Canada and the US will urge manufacturers towards developing advanced bone growth stimulators. Meanwhile, revenues amassed from sales of bone growth stimulators in Europe will contribute US$ 600 Mn in revenues by the end of 2022. Towards the end of forecast period, North America’s bone growth stimulator market is likely to soar at a CAGR of 6.2%.
Application of bone growth stimulators in delayed union & non-union bone fracture treatments is expected to gain traction, reflecting a revenue growth at 5.7% CAGR. Spinal fusion surgeries will account for nearly 25% of the global bone growth stimulator sales in 2017, while their application in oral and maxillofacial surgeries will procure around US$ 250 Mn in global revenues.
Hospitals and clinics are expected to remain largest end-users of bone growth stimulator throughout the forecast period. With more than 43% share, over US$ 800 Mn worth of bone growth stimulators will be sold in hospitals & clinics across the globe by 2022-end. Home care end-use of bone growth stimulator, on the other hand, is expected to create an incremental opportunity of more than US$ 100 Mn by 2022 over 2017.
View Full Report with Table of Content @ https://www.factmr.com/report/54/bone-growth-stimulator-market

Rise in R&D Funding by Private Organisations to Propel Growth of the Global Bone Growth Stimulator Market

Bone growth stimulators facilitate multi-level fusions in bones with high efficiency, playing a pivotal role in spine fusion aftercare of patients. Medical studies are revealing positive outcomes of utilizing electrical bone growth stimulators for spinal fusion process. With a number of favorable government initiatives, coupled with heavy investments made by several private organisations, there has been a robust increase in research & development activities associated with new treatment methods and product development. For example – the North American Spine Foundation, and American Academy of Orthopedic Surgeons are contributing to the development of spinal implants & devices by raising funds for R&D activities, and conducting training programs for physicians worldwide.

Leading players in the market have introduced novel bone growth stimulators in order to cater demand from soaring adoption of affordable minimally-invasive surgeries (MIS). Orthofix, a Texas Company, has introduced new bone growth stimulators, the CervicalStim and the SpinalStim, which have been approved by the European CE Mark as well as the Food and Drug Administration of the U.S. While the out-of-the-office treatment option (non-invasive) has an obvious appeal to it, necessary patient compliance remains a challenge for physicians. However, an application called Stim onTrack has been developed by Orthofix, which offers physicians with real-time data, which enables effective detailing of the patient’s treatment protocol.

North America to Remain Dominant in the Global Bone Growth Stimulator Market

North America will continue to be dominant in the global bone growth stimulator market. Sales of bone growth stimulators are expected to account for the largest revenues in North America, expanding at the highest CAGR through 2022. Europe will remain the second most lucrative market for bone growth stimulators. The market in Middle East & Africa (MEA) will continue to register a sluggish expansion through 2022.

Bone growth stimulation devices will remain sought-after among products in the global market. Revenues from sales of bone growth stimulation devices will account for over half share of the market during the forecast period. In addition, sales of platelet-rich plasma bone growth stimulator, and bone morphogenetic proteins are expected to exhibit the fastest expansion registering similar CAGRs through 2022.

Hospitals & Clinics will Remain the largest End-Users of Bone Growth Stimulators

Based on end-users, sales of bone growth stimulators in academic and research institutes are expected to register the highest CAGR through 2022. Hospitals & Clinics will continue to be the largest end-users of bone growth stimulators, accounting for the highest share of the market over the forecast period. Home care is expected to remain the second most lucrative end-use segment in the global bone growth stimulators market.

Bone growth stimulators are expected to find the largest application in the cases of delayed union & non-union bone fractures, with sales poised to reach US$ 763.4 Mn by 2022-end. Sales of bone growth stimulators in oral & maxillofacial surgeries will account for the lowest revenues during the forecast period, based on application.

Competition Tracking

The report has also profiled key players in the global market for bone growth stimulators, which include Ossatec Benelux B.V., Elizur Corporation, Johnson & Johnson, Arthrex, Inc., DJO Global Inc., Stryker Corporation, Bioventus Inc., Zimmer Biomet Holdings, Inc., Medtronic plc., and Orthofix International N.V.

Grow Your Business From Expert Advice @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=54

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market Insights reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Follow Us on Linkedin: https://www.linkedin.com/company/factmr/

This release was published on openPR.